About the Company
We do not have any company description for Pulmatrix, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $PULM News
Pulmatrix Inc PULM
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update
About Pulmatrix, Inc.Pulmatrix is a clinical-stage biopharmaceutical company focused on the development of novel inhaled therapeutic products intended to prevent and treat respiratory and other ...
Pulmatrix Inc.
PULMATRIX INC's gross profit margin for the third quarter of its fiscal year 2023 has significantly increased when compared to the same period a year ago. Even though sales decreased, the net ...
Pulmatrix Inc.: Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update
March 28, 2024 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious ...
Pulmatrix Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Pulmatrix Inc 2PU
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update
March 28, 2024 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious ...
Loading the latest forecasts...